Monday, November 16, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AInMode Q3 revenue holds near $92.1M, margins slip3 days agoRegulatoryJudge bars Medicare price for Botox over plasma rulelast weekRegulatoryMexico approves Restylane Shaype for jawline first3 days agoBusiness & M&AEvolus posts Q3 loss of $0.09, revenue tops estimateslast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boost4 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekDevices & TechConexeu's first human collagen batch meets its own specs5 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin sales5 days agoBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patch6 days agoRegulatoryFDA clears Shenzhen Bway red/NIR LED face mask6 days ago
Devices & Tech

BTL expands EXOMIND brain stimulation to OCD, adolescents

The noninvasive platform now treats obsessive-compulsive disorder and depression in teens, with three-minute sessions available.

A woman receiving professional facial treatment at a clinic, highlighting beauty and technology.
Photo: Ivan Babydov / Pexels

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Primary document: BTL Expands EXOMIND® Platform with New FDA Clearances · Published: 2026-10-01

BTL announced expanded FDA clearances for EXOMIND, its noninvasive brain stimulation platform, on October 1, 2026. The device entered the U.S. market in 2025 for major depressive disorder in adults. The new clearances add obsessive-compulsive disorder, MDD with comorbid anxiety, and adolescent patients to the platform's approved uses.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

EXOMIND now treats obsessive-compulsive disorder, MDD with comorbid anxiety, and adolescent depression, with sessions as short as three minutes.

The expansion matters because it opens EXOMIND to more patients and addresses a different clinical problem. OCD affects a substantial portion of people worldwide, and the clearance gives practices a new tool for patients whose condition hasn't responded to or who can't tolerate existing treatments. Adolescents struggle with depression—antidepressants either fail or cause side effects that make it harder to sustain care.

Dennis Weimer, MD, a psychiatrist triple board-certified in psychiatry, consultation-liaison psychiatry, and addiction medicine, said in the announcement that EXOMIND has worked well for his depression patients and that the OCD clearance gives him another option. He noted that three-minute sessions make it easier to fit into patients' schedules. Michelle Dees, MD, a board-certified psychiatrist, emphasized that adolescent depression disrupts school, friendships, and family life, and that the adolescent clearance offers clinicians an alternative when antidepressants haven't worked or cause intolerable side effects.

BTL also introduced two operational changes. The platform now offers an intermittent theta burst protocol with sessions as short as three minutes, reducing the time patients must commit to MDD care. The company also launched a new EXOMIND Dual Applicator, which expands how providers can target brain regions and personalize care.

Rohit Mishra, Vice President of Product Strategy & Business Development at BTL, said the company is committed to expanding EXOMIND's capabilities and access to care across age groups and conditions. He stated that EXOMIND is a core part of BTL's portfolio and that the company will continue to invest in its future.

The three-minute theta burst protocol represents a significant shift in how treatment works logistically. For practices managing patient flow and scheduling, shorter sessions mean providers can structure the day with greater adaptability. A patient can receive care in the time it takes to complete intake paperwork at many offices. This matters for keeping patients engaged—they're more likely to complete a course of care when each session fits easily into their schedule.

The Dual Applicator expands the platform's technical reach. By offering providers greater ability to personalize patient care, BTL is positioning EXOMIND as a tool that can adapt to individual patient anatomy and clinical needs rather than a one-size-fits-all device.

BTL is hosting North American EXOMIND Days on October 13–15, 2026, where practices and communities will share experiences and discuss the platform's expanded uses. This event signals the company's intent to build a practitioner community around the device and to educate the market on the new indications.

The company, founded in 1993, operates across dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, and primary care. Its portfolio includes EMSCULPT NEO, EMFACE, EXION, and EMSELLA alongside EXOMIND. BTL holds more than 200 patents and employs over 600 in-house engineers. The breadth of BTL's device portfolio means that practices already using other BTL systems may find EXOMIND a natural addition to their offerings, particularly those in psychiatry or mental health settings.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.

Source: original report ↗

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/btl-expands-exomind-brain-stimulation-ocd-adolescents/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →